Oral Immunotherapy (OIT) for Food Allergies in Toddlers
The short answer
Oral immunotherapy (OIT) is a treatment that gradually introduces small, increasing doses of a food allergen to raise the threshold of tolerance and reduce the risk of severe reactions from accidental exposure. Palforzia (peanut allergen powder) is FDA-approved for peanut allergy in children 4-17 years old, but many allergists offer OIT off-label for younger children and other allergens. OIT does not cure food allergies but can provide significant protection. Success rates for desensitization range from 60-85%, though the maintenance dose must be continued indefinitely. OIT carries risks, including allergic reactions during treatment, and should only be conducted under the supervision of an experienced allergist.
Thousands of parents search for this exact thing. You are not alone.
By Age
What to expect by age
6-12 months
At this age, the focus should be on early allergen introduction rather than OIT treatment. The LEAP study demonstrated that introducing peanut products early (between 4-6 months) in high-risk infants reduced peanut allergy development by 81%. If your baby has been diagnosed with a food allergy, work with a pediatric allergist to determine whether OIT might be considered at a later age. For infants with egg or milk allergies, some allergists begin baked-allergen laddering (introducing the allergen in baked forms first) as an early desensitization approach.
12-36 months
Some allergists begin OIT in this age range, particularly for peanut, milk, and egg allergies. Evidence suggests that starting OIT earlier may lead to better outcomes because the immune system is more malleable in young children. The process involves a supervised initial dose escalation in the allergist's office, followed by daily home dosing with gradual increases every 1-2 weeks. Treatment takes 6-12 months to reach maintenance dose. Common side effects include mild oral itching, abdominal pain, and nausea. Anaphylaxis can occur but is uncommon (1-5% of patients).
3-5 years
This age range has the most data supporting OIT safety and efficacy. Palforzia (FDA-approved peanut OIT) is approved for ages 4-17. For other allergens (milk, egg, tree nuts, sesame), OIT is available off-label through experienced allergists. Factors affecting success include the severity of the allergy, the specific allergen, adherence to daily dosing, and avoidance of exercise and hot showers after dosing (which can increase reaction risk). OIT requires a significant time commitment and ongoing engagement with your allergist. Discuss whether OIT, omalizumab, or a combination approach is best for your child.
What Should You Do?
When to take action
- Your child's food allergy is well-managed with avoidance and you carry epinephrine as prescribed.
- Your child is undergoing OIT under allergist supervision and is tolerating the doses as expected.
- Your child had mild oral itching or stomach discomfort after an OIT dose, which resolved on its own.
- Your child has been diagnosed with a food allergy and you want to discuss OIT as a treatment option.
- You are interested in the differences between OIT, sublingual immunotherapy (SLIT), and omalizumab.
- Your child is having frequent mild reactions during OIT and you want to adjust the protocol.
- Your child's food allergy is significantly affecting their quality of life and you want to explore all options.
- Your child has a severe allergic reaction during OIT (difficulty breathing, widespread hives, vomiting, dizziness) - use epinephrine and call 911.
- Your child accidentally received a double dose of OIT allergen.
- Your child is having symptoms of anaphylaxis at any time: throat tightening, difficulty breathing, fainting, or widespread hives with vomiting.
Sources
Related Resources
Trust your instincts. If something feels wrong, reach out to your pediatrician.
Worrying about your baby means you care. That is a good thing.
Related Medical Concerns
Omalizumab (Xolair) for Food Allergies in Children
Omalizumab (brand name Xolair) received FDA approval in 2024 as the first biologic therapy for food allergies in children ages 1 and older. It works by blocking IgE antibodies, which are responsible for allergic reactions, thereby raising the threshold of allergen needed to trigger a reaction. In clinical trials, after 16-20 weeks of treatment, 67% of participants could tolerate the equivalent of 2-3 peanuts without a reaction, compared to 7% on placebo. Omalizumab does not cure food allergies but provides a significant safety net against accidental exposures. It is given as an injection every 2-4 weeks.
Baby Hives (Urticaria)
Hives are raised, red, itchy welts that can appear suddenly on your baby's skin. They are most often caused by a viral infection or an allergic reaction to food, medication, or an insect bite. While they can look alarming, hives are usually harmless and resolve on their own, though any breathing difficulty needs immediate emergency care.
My Baby Keeps Choking on Food
First, it's important to distinguish between gagging and choking. Gagging is a normal protective reflex that helps babies learn to eat, while true choking is silent and requires immediate intervention. Most "choking" episodes parents describe are actually gagging, which is common and expected as babies explore new textures. However, if your baby frequently struggles with swallowing or shows signs of true choking, it's worth discussing with your pediatrician.
My Baby's Head Shape Looks Abnormal
Many babies develop temporary head shape irregularities that are completely normal. A cone-shaped head from vaginal delivery reshapes within days. Mild positional flattening (plagiocephaly) from sleeping on the back is very common and usually improves with repositioning and tummy time. However, head shape changes involving ridges, a persistently bulging fontanelle, or rapid head growth changes should be evaluated to rule out craniosynostosis.
Achondroplasia (Dwarfism) in Babies
Achondroplasia is the most common form of short-limbed dwarfism, affecting about 1 in 15,000 to 40,000 births. It is caused by a mutation in the FGFR3 gene and is usually apparent at birth with characteristic features including short limbs, a larger head, and a prominent forehead. Intelligence is normal. With monitoring for specific complications and supportive care, children with achondroplasia lead full, active, and independent lives.
Adenoid Hypertrophy and Breathing
Adenoids are lymphoid tissue located behind the nose that help fight infection in young children. When adenoids become enlarged (adenoid hypertrophy), they can block the nasal airway, causing chronic mouth breathing, snoring, nasal speech, and sleep-disordered breathing. Enlarged adenoids are most common between ages 2-7 and are a leading cause of obstructive sleep apnea in young children. Treatment ranges from watchful waiting and nasal steroids to surgical removal (adenoidectomy) if breathing or sleep is significantly affected.